GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Faron Pharmaceuticals Oy (LSE:FARN) » Definitions » Enterprise Value

Faron Pharmaceuticals Oy (LSE:FARN) Enterprise Value : £88.52 Mil (As of Jun. 10, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Faron Pharmaceuticals Oy Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Faron Pharmaceuticals Oy's Enterprise Value is £88.52 Mil. Faron Pharmaceuticals Oy's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil. Therefore, Faron Pharmaceuticals Oy's EV-to-EBIT ratio for today is .

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Faron Pharmaceuticals Oy's Enterprise Value is £88.52 Mil. Faron Pharmaceuticals Oy's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil. Therefore, Faron Pharmaceuticals Oy's EV-to-EBITDA ratio for today is .

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Faron Pharmaceuticals Oy's Enterprise Value is £88.52 Mil. Faron Pharmaceuticals Oy's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil. Therefore, Faron Pharmaceuticals Oy's EV-to-Revenue ratio for today is .


Faron Pharmaceuticals Oy Enterprise Value Historical Data

The historical data trend for Faron Pharmaceuticals Oy's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faron Pharmaceuticals Oy Enterprise Value Chart

Faron Pharmaceuticals Oy Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 110.05 121.13 139.59 184.88 215.17

Faron Pharmaceuticals Oy Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 139.59 120.89 184.88 166.92 215.17

Competitive Comparison of Faron Pharmaceuticals Oy's Enterprise Value

For the Biotechnology subindustry, Faron Pharmaceuticals Oy's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Faron Pharmaceuticals Oy's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Faron Pharmaceuticals Oy's Enterprise Value falls into.



Faron Pharmaceuticals Oy Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Faron Pharmaceuticals Oy's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Faron Pharmaceuticals Oy's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Faron Pharmaceuticals Oy  (LSE:FARN) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Faron Pharmaceuticals Oy's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=88.517/0
=

Faron Pharmaceuticals Oy's current Enterprise Value is £88.52 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Faron Pharmaceuticals Oy's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Faron Pharmaceuticals Oy's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=88.517/0
=

Faron Pharmaceuticals Oy's current Enterprise Value is £88.52 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Faron Pharmaceuticals Oy's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Faron Pharmaceuticals Oy's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=88.517/0
=

Faron Pharmaceuticals Oy's current Enterprise Value is £88.52 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Faron Pharmaceuticals Oy's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Faron Pharmaceuticals Oy Enterprise Value Related Terms

Thank you for viewing the detailed overview of Faron Pharmaceuticals Oy's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Faron Pharmaceuticals Oy (LSE:FARN) Business Description

Traded in Other Exchanges
Address
Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.

Faron Pharmaceuticals Oy (LSE:FARN) Headlines

No Headlines